Te Kāhui Oranga ō Nuku welcomes PMMRC report

25 September 2019

The leading body for obstetrics and gynaecology and women’s health in New Zealand has welcomed the Perinatal and Maternal Mortality Review Committee’s (PMMRC) latest report, calling on government and the health sector to implement its recommendations.
The report investigates the factors contributing to perinatal mortality (stillbirths and baby deaths in the first 28 days of life), maternal deaths and neonatal brain injury (encephalopathy). It shows that the rate of stillbirth has significantly reduced overall since 2007 and has reduced for babies of Māori and NZ European mothers, but not for other ethnic groups.
Chair of the Te Kāhui Oranga ō Nuku of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), Dr Celia Devenish, called for equitable access to pregnancy screening tools, services and treatment.
“Gaps and inequities that exist in maternity services in New Zealand need to be urgently addressed,” Dr Devenish said. “Across New Zealand, groups of women are unable to access the care they need for themselves and their unborn babies. For example, antenatal screening to identify Down syndrome and other conditions should be a choice available for all women in New Zealand. However there is a co-payment required for the scan component of the test, which can exceed $60.
“RANZCOG’s Te Kāhui Oranga ō Nuku supports the PMMRC and its mission to improve the outcomes of mothers and babies in Aotearoa/New Zealand.”

Media Enquiries
Andre Khoury
+61 3 9114 3923
+61 448 735 749
[email protected] 



Te Kāhui Oranga ō Nuku calls for commitment to HPV screening

RANZCOG has called on all political parties to commit to funding for HPV screening, which is a better way to screen for cervical cancer.



Hearing the stories of mesh survivors

RANZCOG acknowledges the pain and suffering of New Zealand women who have experienced serious complications from pelvic mesh implants.



Widening contraceptive choice for women welcomed

Universal funding for long acting reversible contraceptives Mirena and Jaydess from November is increasing choice for New Zealand women, says RANZCOG.